RESEARCH & PUBLICATIONS
Designed in silico.
Tested in the lab.
Our platform builds on research in protein–protein interactions, computational biology, and peptide engineering. Explore selected peer-reviewed studies.
2026
Blood Advances
Disease-specific recognition. Picomolar affinity.
The G14 peptide showed approximately 6.6 pM affinity for a disease-associated platelet receptor variant. In the reported experiments, it disrupted abnormal platelet–VWF interactions without measurable effects on healthy samples.
Developing an artificial intelligence-generated peptide targeting platelet-type von Willebrand disease
Read publication ↗
2025
Nature Communications
Disrupting the interactions that enable infection.
Computationally designed peptide inhibitors blocked viral entry and replication in laboratory cell models, including models of SARS-CoV-2 variants. The work connects protein interaction mapping with the discovery of antiviral candidates.
Human protein interaction networks of ancestral and variant SARS-CoV-2 in organ-specific cells and bodily fluids
Read publication ↗
2022
NAR Genomics and Bioinformatics
A diagnostic assay, built entirely around peptides.
Two designed peptides served as capture and detection reagents in a sandwich ELISA, detecting spike protein down to 100 pg/mL in laboratory mixtures containing cell lysates. Binding was evaluated using ELISA and surface plasmon resonance.
A computational approach to rapidly design peptides that detect SARS-CoV-2 surface protein S
Read publication ↗
2025
International Journal of Molecular Sciences
Finding functional parallels in nature.
An engineered SARS-CoV-2-binding peptide guided the discovery of a canola-derived peptide with related binding and inhibitory activity in the reported experiments. The study points to a route from computational design to natural bioactive discovery.
Artificial Intelligence Reveals Nature: Functional Parallels Between a Designed and a Natural Peptide
Read publication ↗
These studies report experimental findings under defined conditions. They demonstrate research potential and do not establish clinical efficacy or the availability of approved therapeutics or diagnostic products.
THE FOUNDATIONS
Built on years of discovery.
Earlier work established methods for predicting protein interactions and engineering synthetic binding proteins.
THE NEXT DISCOVERY STARTS WITH A CONVERSATION
Let’s ask the next question.
Collaborate with us on the molecular challenges that matter to your research.
Let’s connect ↗